دورية أكاديمية
Value-based payment models and management of newly diagnosed prostate cancer.
| العنوان: | Value-based payment models and management of newly diagnosed prostate cancer. |
|---|---|
| المؤلفون: | Maganty A; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA., Kaufman SR; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA., Oerline MK; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA., Faraj KS; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA., Caram MEV; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.; VA Health Services Research & Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA., Shahinian VB; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Hollenbeck BK; Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. |
| المصدر: | Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (1), pp. e6810. Date of Electronic Publication: 2023 Dec 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012- |
| مواضيع طبية MeSH: | Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/economics , Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/mortality , Medicare*/economics , Accountable Care Organizations*/economics, Male ; Humans ; United States ; Aged ; Aged, 80 and over ; Urologists/economics ; Reimbursement, Incentive/economics ; Health Expenditures |
| مستخلص: | Objective: To examine the effect of urologist participation in value-based payment models on the initial management of men with newly diagnosed prostate cancer. Methods: Medicare beneficiaries with prostate cancer diagnosed between 2017 and 2019, with 1 year of follow-up, were assigned to their primary urologist, each of whom was then aligned to a value-based payment model (the merit-based incentive payment system [MIPS], accountable care organization [ACO] without financial risk, and ACO with risk). Multivariable mixed-effects logistic regression was used to measure the association between payment model participation and treatment of prostate cancer. Additional models estimated the effects of payment model participation on use of treatment in men with very high risk (i.e., >75%) of non-cancer mortality within 10 years of diagnosis (i.e., a group of men for whom treatment is generally not recommended) and price-standardized prostate cancer spending in the 12 months after diagnosis. Results: Treatment did not vary by payment model, both overall (MIPS-67% [95% CI 66%-68%], ACOs without risk-66% [95% CI 66%-68%], ACOs with risk-66% [95% CI 64%-68%]). Similarly, treatment did not vary among men with very high risk of non-cancer mortality by payment model (MIPS-52% [95% CI 50%-55%], ACOs without risk-52% [95% CI 50%-55%], ACOs with risk-51% [95% CI 45%-56%]). Adjusted spending was similar across payment models (MIPS-$16,501 [95% CI $16,222-$16,780], ACOs without risk-$16,140 [95% CI $15,852-$16,429], ACOs with risk-$16,117 [95% CI $15,585-$16,649]). Conclusions: How urologists participate in value-based payment models is not associated with treatment, potential overtreatment, and prostate cancer spending in men with newly diagnosed disease. (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.) |
| References: | Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17‐48. doi:10.3322/caac.21763. Financial Burden of Cancer Care | Cancer Trends Progress Report. Accessed October 6, 2022. https://progressreport.cancer.gov/after/economic_burden. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975‐980. doi:10.1001/jama.280.11.975. Hollenbeck BK, Kaufman SR, Yan P, et al. Urologist practice affiliation and intensity‐modulated radiation therapy for prostate cancer in the elderly. Eur Urol. 2018;73(4):491‐498. doi:10.1016/j.eururo.2017.08.001. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen‐deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822‐1832. doi:10.1056/NEJMsa0910784. Modi PK, Kaufman SR, Herrel LA, et al. Practice‐level adoption of conservative management for prostate cancer. J Oncol Pract. 2019;15(10):e863‐e869. doi:10.1200/JOP.19.00088. McWilliams JM. MACRA — Big fix or big problem? Ann Intern Med. 2017;167(2):122‐124. doi:10.7326/M17-0230. CMS. Merit‐based Incentive Payment System (MIPS) Overview ‐ QPP. Accessed November 15, 2021. https://qpp.cms.gov/mips/overview. Fisher ES, Shortell SM, Kreindler SA, Van Citters AD, Larson BK. A framework for evaluating the formation, implementation, and performance of accountable care organizations. Health Aff. 2012;31(11):2368‐2378. doi:10.1377/hlthaff.2012.0544. Maganty A, Hollenbeck BK, Kaufman SR, et al. Implications of the merit‐based incentive payment system for urology practices. Urology. 2022;169:84‐91. doi:10.1016/j.urology.2022.05.052. Khullar D, Bond AM, Qian Y, O'Donnell E, Gans DN, Casalino LP. Physician practice leaders’ perceptions of Medicare's merit‐based incentive payment system (MIPS). J Gen Intern Med. 2021;9:1‐7. doi:10.1007/s11606-021-06758-w. Golding LP, Nicola GN, Duszak R, Rosenkrantz AB. The quality measure crunch: how CMS topped out scoring and removal policies disproportionately disadvantage radiologists. J Am Coll Radiol. 2020;17(1 Pt B):110‐117. doi:10.1016/j.jacr.2019.08.014. Hollenbeck BK, Bierlein MJ, Kaufman SR, et al. Implications of evolving delivery system reforms for prostate cancer care. Am J Manag Care. 2016;22(9):569‐575. CMS. Medicare Data on Provider Practice and Specialty (MD‐PPAS) | ResDAC. https://resdac.org/cms‐data/files/md‐ppas. Rittenhouse DR, Casalino LP, Shortell SM, et al. Small and medium‐size physician practices use few patient‐centered medical home processes. Health Aff. 2011;30(8):1575‐1584. doi:10.1377/hlthaff.2010.1210. Doctors and clinicians | Provider Data Catalog. Accessed December 10, 2021. https://data.cms.gov/provider‐data/topics/doctors‐clinicians. Medicare Shared Savings Program Accountable Care Organizations (ACO) Provider‐level RIF | ResDAC. Accessed November 14, 2022. https://resdac.org/cms‐data/files/share‐saving‐program‐aco‐provider‐level. Accountable Care Organization Participants—Centers for Medicare & Medicaid Services Data. Accessed January 23, 2023. https://data.cms.gov/medicare‐shared‐savings‐program/accountable‐care‐organization‐participants. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu‐Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335‐1341. doi:10.1200/JCO.2010.31.2330. Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population‐based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709‐717. doi:10.7326/0003-4819-158-10-201305210-00005. Dahabreh IJ, Hayward R, Kent DM. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient‐centred evidence. Int J Epidemiol. 2016;45(6):2184‐2193. doi:10.1093/ije/dyw125. Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med. 2006;145(9):646‐653. doi:10.7326/0003-4819-145-9-200611070-00006. Borza T, Kaufman SR, Yan P, et al. Early effect of Medicare shared savings program accountable care organization participation on prostate cancer care. Cancer. 2018;124(3):563‐570. doi:10.1002/cncr.31081. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001;345(2):99‐106. doi:10.1056/NEJM200107123450205. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258‐1267. doi:10.1016/s0895-4356(00)00256-0. Kralewski J, Dowd B, Knutson D, Tong J, Savage M. The relationships of physician practice characteristics to quality of care and costs. Health Serv Res. 2015;50(3):710‐729. doi:10.1111/1475-6773.12242. Clough JD, McClellan M. Implementing MACRA: implications for physicians and for physician leadership. JAMA. 2016;315(22):2397‐2398. doi:10.1001/jama.2016.7041. Borza T, Oerline MK, Skolarus TA, et al. Association between hospital participation in Medicare shared savings program accountable care organizations and readmission following major surgery. Ann Surg. 2019;269(5):873‐878. doi:10.1097/SLA.0000000000002737. McConnell KJ, Renfro S, Chan BKS, et al. Early performance in Medicaid accountable care organizations: a comparison of Oregon and Colorado. JAMA Intern Med. 2017;177(4):538‐545. doi:10.1001/jamainternmed.2016.9098. Sharma V, Wymer KM, Borah BJ, et al. Cost‐effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy for localized prostate cancer: an analysis of the ProtecT trial. J Urol. 2019;202(5):964‐972. doi:10.1097/JU.0000000000000345. Glance LG, Neuman M, Martinez EA, Pauker KY, Dutton RP. Performance measurement at a tipping point. Anesth Analg. 2011;112(4):958‐966. doi:10.1213/ANE.0b013e31820e778d. Glance LG, Thirukumaran CP, Feng C, Lustik SJ, Dick AW. Association between the physician quality score in the merit‐based incentive payment system and hospital performance in hospital compare in the first year of the program. JAMA Netw Open. 2021;4(8):e2118449. doi:10.1001/jamanetworkopen.2021.18449. McWilliams JM, Hatfield LA, Landon BE, Hamed P, Chernew ME. Medicare spending after 3 years of the Medicare shared savings program. N Engl J Med. 2018;379(12):1139‐1149. doi:10.1056/NEJMsa1803388. Hollenbeck BK, Kaufman SR, Borza T, et al. Accountable care organizations and prostate cancer care. Urol Pract. 2017;4(6):454‐461. doi:10.1016/j.urpr.2016.11.001. Cole AP, Krasnova A, Ramaswamy A, et al. Prostate cancer in the Medicare shared savings program: are accountable care organizations associated with reduced expenditures for men with prostate cancer? Prostate Cancer Prostatic Dis. 2019;22(4):593‐599. doi:10.1038/s41391-019-0138-1. Hawken SR, Ryan AM, Miller DC. Surgery and Medicare shared savings program accountable care organizations. JAMA Surg. 2016;151(1):5‐6. doi:10.1001/jamasurg.2015.2772. Pham HH, O'Malley AS, Bach PB, Saiontz‐Martinez C, Schrag D. Primary care physicians’ links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med. 2009;150(4):236‐242. doi:10.7326/0003-4819-150-4-200902170-00004. Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV. Time trends and variation in the use of active surveillance for management of low‐risk prostate czancer in the US. JAMA Netw Open. 2023;6(3):e231439. doi:10.1001/jamanetworkopen.2023.1439. Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J. Cost of new Technologies in Prostate Cancer Treatment: systematic review of costs and cost effectiveness of robotic‐assisted laparoscopic prostatectomy, intensity‐modulated radiotherapy, and proton beam therapy. Eur Urol. 2017;72(5):712‐735. doi:10.1016/j.eururo.2017.03.028. Making Care Primary (MCP) Model | CMS Innovation Center. Accessed August 5, 2023. https://innovation.cms.gov/innovation‐models/making‐care‐primary. |
| معلومات مُعتمدة: | F32 CA275021-01 United States CA NCI NIH HHS; R01CA275993-01 United States CA NCI NIH HHS; R01 HS025707 United States HS AHRQ HHS; F32 CA275021 United States CA NCI NIH HHS; R01 CA275993 United States CA NCI NIH HHS; R01HS025707 Agency for Healthcare Research and Quality; RSGI-21-097-01-HOPS American Cancer Society; F32 CA275021-01 United States CA NCI NIH HHS; R01CA275993-01 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Medicare; prostate cancer; quality of care; value‐based payment |
| تواريخ الأحداث: | Date Created: 20231226 Date Completed: 20240805 Latest Revision: 20240805 |
| رمز التحديث: | 20240806 |
| مُعرف محوري في PubMed: | PMC10807592 |
| DOI: | 10.1002/cam4.6810 |
| PMID: | 38146905 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2045-7634 |
|---|---|
| DOI: | 10.1002/cam4.6810 |